Oncopharmpod
Trilaciclib, Cemiplimab & GU Updates
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:19:58
- Mas informaciones
Informações:
Sinopsis
Topics covered: 1. Trilaciclib's approval to minimize bone marrow suppression 2. Cemiplimab's approval for mNSLC with high PD-L1 expression 3. A brief anti-BCMA CAR-T phase II trial in multiple myeloma 4. Confirmation of enfortumab vedotin's benefit in metastatic bladder cancer 5. More of the same with lenvatinib + pembrolizumab in mRCC
